Effect of Telmisartan on Cardiovascular Markers in Cardiac Patients: In Honor of Pavel Prikryl
| Authors | |
|---|---|
| Year of publication | 2022 |
| Type | Article in Proceedings |
| Conference | Noninvasive methods in cardiology 2022 |
| MU Faculty or unit | |
| Citation | |
| Web | https://is.muni.cz/do/med/noninvasive_methods_in_cardiology/Noninvasive_methods_in_cardiology_2022.pdf |
| Keywords | Telmisartan; Cardiovascular Markers; Cardiac Patients |
| Description | The action of an angiotensin receptor blocker (ARB) and of an angiotensin-converting enzyme (ACE) inhibitor alone or in combination on a number of cardiovascular biomarkers is evaluated in 18 outpatients with essential hypertension, using a double-blind, randomized, crossover design. Study stages lasted 7 days, separated by a 2-day washout. Treatment was administered daily, upon awakening. During each stage (placebo, ARB treatment, ACE inhibitor treatment, combined treatment), blood pressure, heart rate, cardiac output, ejection fraction and brain natriuretic peptide (BNP) as well as angiotensin II, plasma renin activity and bradykinin were measured four times a day, at 6-hour intervals. The least squares fit of a 24-hour cosine curve to each individual 7-day record assessed the circadian variation, further summarized across all 18 patients by population-mean cosinor. Parameter tests assessed treatment effect and any difference in the efficacy of the two kinds of medication. Results indicate that BNP and other cardiovascular variables are circadian periodic. Treatment with Telmisartan (ARB) and Lisinopril (ACE inhibitor) have positive effects on cardiovascular health. BNP is greatly decreased with both treatments. Combined treatment with both drugs achieve even larger effects than with any one drug used alone. Whether treatment effects can be further optimized by timing remains to be determined, whether in terms of important cardiac markers and/or adverse cardiovascular outcomes. |